Related Experiment Videos
Prospective controlled studies on prophylaxis: an Italian approach
1Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Milan, Italy. alessandro.gringeri@unimi.it
Summary
Prophylactic clotting factor infusions may delay joint damage in hemophilia A, but prospective studies are needed to confirm benefits and optimize treatment. The ESPRIT trial will provide definitive data on prophylaxis versus on-demand care.
Area of Science:
- Hematology
- Orthopedics
- Clinical Trials
Background:
- Retrospective data suggest prophylactic clotting factor infusions delay arthropathy in hemophilia A and B.
- However, retrospective studies have limitations including selection bias and confounding factors.
- Optimal prophylaxis strategies (dose, interval, initiation/cessation) and cost-effectiveness require further investigation.
Purpose of the Study:
- To provide definitive prospective data on the efficacy and safety of prophylaxis versus on-demand treatment in severe hemophilia A.
- To compare the impact of prophylaxis and on-demand regimens on joint deterioration and bleeding frequency.
Main Methods:
- The ESPRIT (Evaluation Study on Prophylaxis: a Randomized Italian Trial) is a prospective, randomized, 10-year study.
- It compares prophylaxis and on-demand clotting factor infusion regimens.
- The study focuses on patients with severe hemophilia A.
Main Results:
- This section is not applicable as the study is currently underway and results are not yet available.
Conclusions:
- Prospective data are essential to establish evidence-based guidelines for hemophilia treatment.
- The ESPRIT trial aims to clarify the role of prophylaxis in preventing joint damage and reducing bleeds.
- Further research is needed on quality of life and cost-effectiveness of prophylactic treatment.